Skip to search formSkip to main contentSkip to account menu

annamycin

Known as: 2'-iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin, 5,12-naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-l-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)- 
A lipophilic, anthracycline antineoplastic antibiotic. Annamycin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1996
1996
1996
A major factor in limiting the efficacy of anthracyclines is overexpression of the MDR1-encoded p-glycoprotein (p-gp). A new… 
1995
1995
Annamycin (Ann) is a non‐cross‐resistant lipophilic anthracy‐cline antibiotic optimally suited for liposome delivery. We studied… 
1995
1995
Annamycin (Ann) is a new lipophilic anthracycline antibiotic with a marked ability to circumvent typical multidrug resistance… 
Highly Cited
1994
Highly Cited
1994
The lipophilic anthracycline antibiotic annamycin (Ann) was entrapped in liposomes of different size [median diameter: 1.64… 
Highly Cited
1993
Highly Cited
1993
The effect of the topoisomerase II inhibitor doxorubicin and its non-cross-resistant analogue annamycin on DNA degradation and… 
1993
1993
Annamycin (AN) is an anthracycline antibiotic with high affinity for lipid membranes which is being developed for clinical… 
1990
1990
We evaluated the entrapment of 21 different water-insoluble aglycones or anthracycline antibiotics in multilamellar liposomes…